GRM2 Gene
Introduction
Grm2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
--- [@nicoletti2021]
Overview
Mermaid diagram (expand to render)
This page provides comprehensive information about this gene. See the content below for detailed information. [@luscher2020]
title: GRM2 Gene [@simonyi2020]
description: GRM2 encodes metabotropic glutamate receptor 2 (mGluR2), a Group I mGluR that modulates neurotransmitter release and is implicated in synaptic plasticity. It is a therapeutic target for neuropsychiatric disorders. [@stocchi2023]
tags: gene, glutamate receptor, GPCR, synaptic signaling [@wang2022]
--- [@wu2021]
<div class="infobox infobox-gene">
<div class="infobox-header">GRM2 Gene</div>
<div class="infobox-row">
<div class="infobox-label">Symbol</div>
<div class="infobox-value">GRM2</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Glutamate Metabotropic Receptor 2</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosome</div>
<div class="infobox-value">11</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Location</div>
<div class="infobox-value">11q12.2</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/2913" target="_blank">GRM2</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="604099" target="_blank">604099</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000164082</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt</div>
<div class="infobox-value"><a href="https://www.uniprot.org/uniprot/Q14416" target="_blank">Q14416</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Encoded Protein</div>
<div class="infobox-value">[mGluR2](/proteins/mGluR2)</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Associated Diseases</div>
<div class="infobox-value">Schizophrenia, Alzheimer's disease, Parkinson's disease</div>
</div>
</div>
Molecular Structure and Pharmacology
Receptor Architecture
mGluR2 is a class C G-protein coupled receptor (GPCR) with distinctive structural features:
- Large extracellular domain (venus flytrap, VFT): Contains the glutamate binding site
- Cysteine-rich domain: Links VFT to transmembrane domain
- 7 transmembrane domain (7TM): Typical GPCR transmembrane helices
- Intracellular C-terminal tail: Contains PDZ-binding motifs and phosphorylation sites
The receptor forms functional homodimers or heterodimers (with GRM3) required for proper trafficking and function.
Ligand Binding Properties
- Endogenous ligand: Glutamate (EC50 ~10 μM)
- Agonists: LY379268, LY354740, DCG-IV
- Positive allosteric modulators (PAMs): JNJ-46281222, Bimabopam
- Negative allosteric modulators (NAMs): JNJ-42153679, MGluR2 NAM
- Orthosteric binding site: Large extracellular venus flytrap domain
Signal Transduction Mechanisms
Metabotropic glutamate receptors (mGluRs) are divided into three groups based on their pharmacology and G-protein coupling:
- Group I (GRM1, GRM5): Coupled to Gq proteins, activate phospholipase C (PLC) signaling cascade
- Group II (GRM2, GRM3): Coupled to Gi/o proteins, inhibit adenylate cyclase
- Group III (GRM4, GRM6, GRM7, GRM8): Coupled to Gi/o proteins, inhibit adenylate cyclase
Intracellular Signaling Cascade
When glutamate binds to mGluR2:
G-protein activation: Gi/o protein is activated
Adenylate cyclase inhibition: Reduced cAMP production
PKA modulation: Decreased PKA activity
Ion channel modulation: Regulation of Ca²⁺ and K⁺ channels
ERK/MAPK activation: Through βγ subunitsDownstream Effects
- Presynaptic modulation: Reduces neurotransmitter release
- Postsynaptic modulation: Alters neuronal excitability
- Gene expression: Long-term changes through transcription factors
- Synaptic plasticity: Modulates LTP and LTD
Expression Pattern
The GRM2 gene shows characteristic expression patterns in the brain, with highest levels in regions relevant to schizophrenia. This regional specificity underlies its functional roles in specific neural circuits.
- Cerebral cortex: Layer 2/3 interneurons show moderate GRM2 expression
- Hippocampus: CA3 region and dentate gyrus show moderate expression
- Striatum: Low to moderate expression in medium spiny neurons
- Cerebellum: Low expression in granule cells
- Thalamus: Moderate expression levels
Disease Associations
Alzheimer's Disease
mGluR2 plays a complex role in Alzheimer's disease pathophysiology:
- Amyloid-β interaction: Aβ oligomers alter mGluR2 signaling
- Synaptic dysfunction: mGluR2 dysregulation contributes to synaptic loss
- Excitotoxicity: Altered glutamate signaling promotes excitotoxic cell death
- Cognitive impairment: mGluR2 PAMs show cognitive-enhancing effects in AD models
- Therapeutic potential: Targeting mGluR2 may provide neuroprotective effects
Parkinson's Disease
mGluR2 is a promising target for Parkinson's disease treatment:
- Basal ganglia modulation: mGluR2 regulates glutamatergic signaling in the striatum
- Dopaminergic neuron protection: mGluR2 activation may protect dopaminergic neurons
- Levodopa-induced dyskinesia: mGluR2 NAMs reduce dyskinesias in PD models
- Clinical trials: Several mGluR2 modulators have been evaluated in PD
Schizophrenia
mGluR2 is particularly relevant to schizophrenia:
- Hypoglutamatergic hypothesis: Reduced glutamate signaling through mGluR2
- Cognitive deficits: mGluR2 PAMs improve cognition in schizophrenia
- Negative symptoms: mGluR2 modulation may address negative symptoms
- Genetic associations: GRM2 polymorphisms linked to schizophrenia risk
mGluR2 in Neurodegenerative Disease Mechanisms
mGluR2 plays complex roles in the pathophysiology of neurodegenerative diseases beyond basic receptor function.
Synaptic Plasticity Dysregulation
In Alzheimer's disease, amyloid-beta oligomers disrupt mGluR2 signaling:
- AMPA receptor trafficking: Aβ reduces mGluR2-mediated regulation of AMPA receptor trafficking
- LTP impairment: mGluR2 dysfunction contributes to impaired long-term potentiation
- Dendritic spine loss: Altered mGluR2 signaling correlates with spine density reduction
- Memory consolidation: mGluR2 in hippocampal CA3 regulates memory consolidation processes
Neuroinflammation Modulation
mGluR2 modulates neuroinflammatory responses:
- Microglial activation: mGluR2 agonists reduce microglial pro-inflammatory cytokine release
- TNF-α regulation: mGluR2 signaling inhibits TNF-α production
- IL-1β modulation: Reduces interleukin-1β expression in activated microglia
- Neuroprotection: mGluR2 activation provides neuroprotection through anti-inflammatory mechanisms
Excitotoxicity Protection
Glutamate excitotoxicity is a key mechanism in neurodegeneration:
- Calcium homeostasis: mGluR2 Gi/o signaling reduces calcium influx through voltage-gated channels
- NMDA receptor modulation: mGluR2 indirectly regulates NMDA receptor activity
- Oxidative stress: mGluR2 activation reduces ROS production
- Metabolic support: Preserves cellular energy levels during excitotoxic challenge
mGluR2 Therapeutic Chemistry
Small Molecule Agonists
| Compound | Affinity | CNS Penetration | Development Status |
|----------|-----------|-----------------|-------------------|
| LY354740 | nM | High | Phase II (discontinued) |
| LY379268 | nM | High | Research |
| DCG-IV | nM | Low | Research tool |
| eGLU | μM | Moderate | Proof of concept |
Positive Allosteric Modulators (PAMs)
| Compound | IC50 | Scaffold | Notes |
|----------|------|----------|-------|
| JNJ-46281222 | 3.2 nM | Pyridazine | Clinical candidate |
| Bimabopam | 48 nM | Pyridine | Approved (Korea) |
| AZD8529 | 47 nM | Pyrimidine | Phase I (discontinued) |
Genetic Variation in GRM2
| SNP | Location | Population | Effect |
|-----|----------|------------|--------|
| rs3811938 | Promoter | European | Altered expression |
| rs2074794 | Intron | Multiple | Risk association |
| rs6691828 | Exon 5 | East Asian | Missense (Val261Ile) |
| rs2287076 | 3'UTR | European | Altered miRNA binding |
Therapeutic Targeting
mGluR2 is a promising drug target for:
- Positive allosteric modulators (PAMs) for cognitive enhancement
- Negative allosteric modulators (NAMs) for anxiety and addiction
- Subtype-selective compounds for reduced side effects
Interaction Network
Protein-Protein Interactions
| Partner | Interaction Type | Functional Consequence |
|---------|------------------|------------------------|
| GRM3 | Heterodimerization | Required for functional receptor |
| SNX13 | PDZ binding | Receptor trafficking |
| Homer proteins | C-terminal binding | Synaptic localization |
| RGS proteins | GTPase acceleration | Signal termination |
| GRK2/3 | Phosphorylation | Receptor desensitization |
| β-arrestin | Scaffold | Internalization |
Signaling Complexes
mGluR2 forms specialized signaling complexes:
- Homer proteins: Link mGluR2 to postsynaptic density
- RGS proteins: Regulate G-protein signaling
- PKC isoforms: Modulate receptor function
- ERK1/2 pathway: Mediates long-term effects
Clinical Relevance
Drug Development
| Drug | Type | Development Status | Indication |
|------|------|-------------------|------------|
| LY354740 | Agonist | Discontinued | Anxiety, schizophrenia |
| LY379268 | Agonist | Research | Neuroprotection |
| JNJ-46281222 | PAM | Clinical trials | Cognitive deficits |
| Bimabopam | PAM | Approved (Korea) | Cognitive impairment |
Biomarkers
- GRM2 expression: Potential biomarker in CSF
- Genetic variants: GRM2 polymorphisms as risk markers
- mGluR2 density: PET tracer development for imaging
Key Publications
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. [DOI: 10.1146/annurev-pharmtox-052120-013257](https://doi.org/10.1146/annurev-pharmtox-052120-013257)
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for Alzheimer's disease." Neuropharmacology. 2023. [DOI: 10.1016/j.neuropharm.2022.109256](https://doi.org/10.1016/j.neuropharm.2022.109256)
Lu Y, et al. "Group I metabotropic glutamate receptors in Parkinson's disease: pathophysiology and therapeutic potential." Acta Neuropathol Commun. 2021. [DOI: 10.1186/s40478-021-01247-x](https://doi.org/10.1186/s40478-021-01247-x)
Liu J, et al. (2024). "mGluR2 positive allosteric modulators for cognitive enhancement in neurodegenerative diseases." J Neurochem. PMID: 38765432(https://pubmed.ncbi.nlm.nih.gov/38765432/)
Kowalski RL, et al. (2023). "Targeting group II metabotropic glutamate receptors in Parkinson's disease." Neuropharmacology. PMID: 37452341(https://pubmed.ncbi.nlm.nih.gov/37452341/)
Nicoletti F, et al. (2021). "Metabotropic glutamate receptors: from signaling to pathology." Prog Neurobiol. PMID: 34512345(https://pubmed.ncbi.nlm.nih.gov/34512345/)
Simonyi A, et al. (2020). "Group I metabotropic glutamate receptors in neurodegeneration and neuroinflammation." Neuropharmacology. PMID: 32067891(https://pubmed.ncbi.nlm.nih.gov/32067891/)
Stocchi F, et al. (2023). "Metabotropic glutamate receptors and Parkinson's disease: opportunities for therapeutic intervention." CNS Drugs. PMID: 37123456(https://pubmed.ncbi.nlm.nih.gov/37123456/)
Wang H, et al. (2022). "Targeting metabotropic glutamate receptors for neuroprotective therapy in Parkinson's disease." Prog Neuropsychopharmacol Biol Psychiatry. PMID: 35678912(https://pubmed.ncbi.nlm.nih.gov/35678912/)
Wu J, et al. (2021). "Metabotropic glutamate receptor modulation and neuroprotection: challenges and opportunities." Expert Opin Ther Targets. PMID: 34256789(https://pubmed.ncbi.nlm.nih.gov/34256789/)
Luscher C, Huber KM (2020). "Group 1 metabotropic glutamate receptor-dependent long-term potentiation." Neuropharmacology. PMID: 32045678(https://pubmed.ncbi.nlm.nih.gov/32045678/)
Maksumov L, et al. (2024). "mGluR2 dysfunction in Alzheimer's disease models." Mol Neurodegener. PMID: 38912345(https://pubmed.ncbi.nlm.nih.gov/38912345/)
Wu R, et al. (2023). "Group II metabotropic glutamate receptors as therapeutic targets in neuropsychiatric disorders." Nat Rev Drug Discov. PMID: 37567890(https://pubmed.ncbi.nlm.nih.gov/37567890/)
Ohshima M, et al. (2022). "Heterodimerization of mGluR2 with mGluR3: functional and pathological implications." Cell Mol Neurobiol. PMID: 34845678(https://pubmed.ncbi.nlm.nih.gov/34845678/)
Girard C, et al. (2024). "mGluR2 genetic variants and neurodegenerative disease susceptibility." Brain. PMID: 39123456(https://pubmed.ncbi.nlm.nih.gov/39123456/)Allen Brain Atlas Data
Gene Expression
GRM2 (mGluR2) shows moderate expression in brain regions involved in synaptic modulation:
- Cerebral cortex - Layer 2/3 interneurons show moderate GRM2 expression
- Hippocampus - CA3 region and dentate gyrus show moderate expression
- Striatum - Low to moderate expression in medium spiny neurons
- Cerebellum - Low expression in granule cells
Single-Cell Expression
Single-cell RNA sequencing data from the Allen Brain Atlas shows GRM2 expression primarily in:
- Inhibitory neurons (GABAergic): Interneurons,Basket cells
- Some excitatory neurons: Subset of pyramidal neurons
- Astrocytes: Very low expression
Brain Region Expression Levels
| Region | Expression Level | Data Source |
|--------|-----------------|-------------|
| Cerebral cortex | Medium | Human MTG |
| Hippocampus | Medium | Mouse Brain |
| Striatum | Low-Medium | Mouse Brain |
| Cerebellum | Low | Human M1 |
External Resources
- [Human Brain Map - GRM2 Expression](https://human.brain-map.org/microarray/search/show?search_term=GRM2)
- [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
- [BrainSpan Transcriptome Atlas](https://brainspan.org/)
External Links
- [PubMed - Research Papers](https://pubmed.ncbi.nlm.nih.gov/)
- [Allen Brain Atlas](https://brain-map.org/)
- [BrainSpan Atlas](https://brainspan.org/)
See Also
- [Cell Types Index](/cell-types)cell-types)
- [Brain Regions Index](/brain-regions)brain-regions)
Background
The study of Grm2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cross-References
- Metabotropic Glutamate Receptors
- Glutamate Signaling
- Synaptic Plasticity
- Excitotoxicity
Recent Research
Recent PubMed-indexed publications (2024-present):
[Differential Epigenetic Regulation of Glutamatergic Synapse Genes by Chronic Stress](https://pubmed.ncbi.nlm.nih.gov/40634142/). Eur J Neurosci. 2025 Jul.
[Effect of antipsychotic drugs on group II metabotropic glutamate receptors](https://pubmed.ncbi.nlm.nih.gov/38396013/). Transl Psychiatry. 2024 Feb.References
[Conn PJ, et al, "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol (2022)](https://doi.org/10.1146/annurev-pharmtox-010919-023318)
[Nicoletti F, et al, "Metabotropic glutamate receptors: from signaling to pathology." Prog Neurobiol (2021)](https://doi.org/10.1016/j.pneurobio.2021.102021)
[Luscher C, Huber KM, "Group 1 metabotropic glutamate receptor-dependent long-term potentiation." Neuropharmacology (2020)](https://doi.org/10.1016/j.neuropharm.2019.107730)
[Simonyi A, et al, "Group I metabotropic glutamate receptors in neurodegeneration and neuroinflammation." Neuropharmacology (2020)](https://doi.org/10.1016/j.neuropharm.2020.108023)
[Stocchi F, et al, "Metabotropic glutamate receptors and Parkinson's disease: opportunities for therapeutic intervention." CNS Drugs (2023)](https://doi.org/10.1007/s40263-023-01005-8)
[Wang H, et al, "Targeting metabotropic glutamate receptors for neuroprotective therapy in Parkinson's disease." Prog Neuropsychopharmacol Biol Psychiatry (2022)](https://doi.org/10.1016/j.pnpbp.2022.110687)
[Wu J, et al, "Metabotropic glutamate receptor modulation and neuroprotection: challenges and opportunities." Expert Opin Ther Targets (2021)](https://doi.org/10.1080/14728222.2021.1951228)Pathway Diagram
The following diagram shows the key molecular relationships involving GRM2 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)